Compared to Estimates, Lilly (LLY) Q3 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Lilly (LLY) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compa...
Novo Nordisk, Eli Lilly stocks see boost on obesity drugs
Novo Nordisk (NVO) shares rose as the drugmaker's third-quarter profits jumped 56% year-over-year, fueled by surging demand for its obesity drugs Ozempic and Wegovy. Eli Lilly (LLY) shares also saw...
Eli Lilly sees strong 3Q sales fueled by Mounjaro but cuts profit outlook
Eli Lilly and Co (NYSE:LLY) reported impressive third-quarter revenue as its diabetes drug Mounjaro exceeded sales expectations. The blockbuster drug generated quarterly sales of $1.41 billion, mar...
Eli Lilly results top estimates on Mounjaro strength but slashes full-year profit outlook
CNBC's Joe Kernen reports on the company's quarterly earnings results.
Eli Lilly Stock Falls as Earnings Guidance Slashed Dramatically
Lilly slashes its guidance for full-year earnings to a range of $6.50 to $6.70 a share, having raised its outlook in August to a range of $9.70 to $9.90.
Eli Lilly's stock drops after surprise profit is reported but full-year outlook was slashed
Shares of Eli Lilly & Co. LLY, +0.10% dropped 1.8% in premarket trading Thursday, after the drug giant reported a surprise third-quarter profit but slashed its full-year outlook, due primarily to a...
Eli Lilly beats quarterly revenue estimates on Mounjaro strength
Eli Lilly beat Wall Street's revenue estimates for the third quarter on Thursday, lifted by strong demand for its diabetes drug Mounjaro that brought in over a billion dollars in sales.
Weight-loss drug maker reports 56% profit surge, as it continues to limit supplies
Novo Nordisk said Thursday it's still struggling to meet demand for its wildly popular weight-loss medications as its third-quarter profit jumped.
Curious about Lilly (LLY) Q3 Performance? Explore Wall Street Estimates for Key Metrics
Evaluate the expected performance of Lilly (LLY) for the quarter ended September 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metric...
Why Beam and Verve Therapeutics Shares Soared While Eli Lilly Soured Today
The trio was involved in a deal for gene-editing programs. The arrangement is potentially worth $600 million.
Verve Stock Soars On $250 Million Eli Lilly Deal
Lilly will pay $250 million to Beam for the rights to three gene-editing drugs from Verve. VERV stock and Beam stock skyrocketed.
Eli Lilly Stock Has Quadrupled in 3 Years. Could a Weight-Loss Drug Approval Make It Happen Again?
Speculation and hype created the bulk of Eli Lilly's bullishness of late rather than plausible fundamentals. The rampant speculation around Mounjaro leaves Lilly stock highly vulnerable to bearish ...
Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?
Roche spent $7.1 billion on a company, primarily because of an IBD therapy. Pfizer just got approval for a pill to treat ulcerative colitis.
Eli Lilly diabetes drug Mounjaro will be in focus when the drugmaker reports earnings next week
Eli Lilly and Co (NYSE:LLY) is scheduled to report earnings before the market opens on Thursday, with analysts expecting revenue growth but an earnings decline. The drugmaker is expected to post a...
Eli Lilly bowel disease drug approved in US
Eli Lilly and Co (NYSE:LLY) has announced that its Omvoh drug has been approved by the US Food and Drug Administration to treat types of inflammatory bowel disease. Following a third-phase 12-week ...
Related Companies